Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » Fluidigm Targets $48.7M in Net Proceeds from Public Offering

Fluidigm Targets $48.7M in Net Proceeds from Public Offering

Aug 16, 2012
|
staff reporter

NEW YORK (GenomeWeb News) – Fluidigm today announced a public offering of its shares that is expected to raise $48.7 million in net proceeds.

The South San Francisco, Calif.-based firm is offering 3,660,000 shares of its common stock at $14.25 per share. The offering is expected to close on or about Aug. 21, and proceeds will go toward R&D, commercialization of its products, working capital, and other general corporate use, Fluidigm said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Not Taking the Post

Following discrimination allegations, NICHD's Constantine Stratakis withdraws from a new position at the Research Institute of the McGill University Health Center, Science reports.

Threats Over WHO Funding

US President Donald Trump has threatened to cut World Health Organization funding over its pandemic response, which would affect its ability to do its work and which he might not be able to do.

Sales Stopped

The US Securities and Exchange Commission has halted the sales of a handful of stocks over claims made about the coronavirus.

Nature Papers Examine Single-Cell RNA Sequencing Protocols, Describe New Labeling Approach

In Nature this week: comparative analyses of single-cell RNA sequencing protocols uncover differences between approaches, and more.

May
06
Featured Webinar

The Role of Single-Cell Functional Biomarkers in Next-Generation Cancer Therapies

Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.

What's Popular?

In PCR

  1. Reanalysis of Flu-Like Illnesses in Wuhan Suggests Coronavirus Community Transmission in January

  2. FDA Grants Emergency Use Authorization for BD Coronavirus Test Kit

  3. With Sputum Test for SARS-CoV-2, MicroGen Dx Aims to Challenge Quest, LabCorp

  4. FDA Issues Emergency Use Authorization for Viracor Eurofins Coronavirus LDT

  5. Stanford Health Care Receives Emergency Use Authorization for SARS-CoV-2 Test

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.